東富龍科技集團有限公司很榮幸參與該項目，并為新的ACES設施提供了MiniKUFill一體化灌裝凍干系統、一次性系統和其他相關設備，共同幫助加快了生產病毒疫苗的良好生產規范（GMP）設施的建設，特別是針對埃博拉和拉沙熱等低收入和中等收入國家（LMICs）疾病的疫苗。并因及時交貨和現場高效安裝而受到客戶的高度評價。

Tofflon Science and Technology Group Co., Ltd. Was honored to participate in the project and provided the new ACES facility with the MiniKUFill integrated filling and lyophilization system, Single-Use Systems and other related equipment, which together helped accelerate the construction of the Good Manufacturing Practice (GMP) facility for the production of viral vaccines especially for diseases in low- and middle-income countries (LMICs) such as Ebola and Lassa Fever, and was highly lauded by the customer for timely delivery and efficient installation on site.

東富龍的MiniKUFill等設備使30,000平方米的研發和中試制造工廠實現了從上游原料藥生產到下游制劑產品的高度靈活的模塊化生產。它可以適應在同一條生產線上生產不同的疫苗平臺。同時，該平臺還將為新加坡本地生態系統以及中低收入國家的研發實體創造培訓機會。

東富龍將持續深耕生物制藥領域，努力為國內外生物制藥企業帶來更好的設備和耗材，為行業的進步和發展貢獻力量。

Tofflon's MiniKUFill and other equipment have enabled the 30,000 square-meter R&D and pilot manufacturing plant to achieve highly flexible modular production from upstream drug substance production to downstream drug products. It can be adapted for the production of different vaccine platforms on the same production line. At the same time, the platform will also create training opportunities for the local Singapore ecosystem as well as R&D entities in LMICs.

Tofflon will continue to develop the field of biopharmaceuticals, strive to bring better equipment and consumables to biopharmaceutical companies at home and abroad, and contribute to the progress and development of the industry.